Thirty-four state and territory attorneys general sent a letter today to federal health agencies asking the federal government to exercise march-in drug rights for remdesivir as a way "to help increase the supply of this drug and lower the price so it is accessible to our state residents."
The big picture: March-in rights — which would allow a patented drug developed with federal dollars to be licensed out to third parties — have never been exercised before. Gilead Sciences, the manufacturer and patent holder of remdesivir, did not immediately respond to requests for comment.
